Aubagio significantly reduced risk of new clinical relapse or MRI lesion in MS study

3 October 2013

French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme announced positive new data from the TOPIC study of its once-daily, oral Aubagio (teriflunomide) at the 29th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS), which include the following:

Aubagio 14mg significantly reduced the risk of a new clinical relapse or MRI lesion over the two-year study period. There was a 35% reduction among patients who received Aubagio 14mg compared to placebo (p=0.0003).

As measured by MRI over the two-year study period, there was a 5% increase in total lesion volume among patients treated with Aubagio 14mg compared to a 28% increase among patients treated with placebo (p=0.0374). In addition, there was a 59% reduction in gadolinium-enhancing T1 lesions among patients treated with Aubagio 14mg compared to placebo (p=0.0008).

Similar results were observed for the 7mg dose, though the effects did not achieve statistical significance on some endpoints, the companies noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK